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A B S T R A C T
The objectives of these GLP US EPA OPPTS 970.3800 and 970.3700 studies were to examine the effects of
tetrabromobisphenol A (TBBPA) at oral doses of 10, 100 or 1000mg/kgBW/day over the course of
2 generations on growth aswell as behavioral, neurological and neuropathologic functions in offspring. In
a separate study the inﬂuence of oral TBBPA (0, 100, 300 or 1000mg/kgBW/d) was examined on
embryonic/fetal development from gestation days (GDs) 0–19. In the reproductive study, exposure to
100-mg/kgBW/d TBBPA resulted in a decrease in circulating, peripheral thyroxine (T4) levels in rats that
were not accompanied by any marked alterations in triiodothyronine (T3) and thyroid stimulating
hormone (TSH). These ﬁndings are explainable on the basis of induction of rat liver catabolism, a
phenomenon that may be species-speciﬁc and not relevant for humans. TBBPA at up to 1000mg/kgBW/d
was not associated with any signiﬁcant non-neurological effects on reproduction, growth and
development. A subtle reduction, of unknown biological relevance, in the thickness of the parietal
cortices of 11-day-old F2 pups in the 1000mg/kgBW/d group was noted. This change was not
accompanied by evidence ofmicro-anatomic changes. No estrogenic effects sufﬁcient to affectmacro and
micro anatomy, fertility, reproduction, development, survival or behavior were detected in the
embryofetal development study or in the multigenerational study. No other TBBPA-related effects on
developmental neurotoxicity/neuropathology were detected. In the developmental study no TBBPA
related change in mortality rate was observed in any of the dams. No other signiﬁcant test article-related
effects were noted. The no observed effect level (NOEL) for maternal and developmental toxicity was
1000mg/kgBW/d, the highest dose evaluated.
ã 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Because of their effectiveness and in order to meet ﬁre safety
standards, organobromide ﬂame retardants, such as 2,20,6,60-
tetrabromo-4,40-isopropylidenediphenol (tetrabromobisphenol A,
TBBPA), have been incorporated into a variety of consumer
products including electrical equipment, and furniture (ARCADIS,
2011). TBBPA is an efﬁcacious ﬁre retardant, which partially
accounts for its annual global production of more than 170kt in
2004 (ECB, 2006), used primarily in epoxy resin printed circuit
boards.
Despite its effectiveness as a ﬁre retardant, concerns have been
raised that TBBPA can leach into the environment, producing
adverse effects on ecosystems and human health (Decherf and
Demeneix 2011). In vitro studies reported binding of TBBPA to
estrogen hormone receptors at high concentrations (Gosavi et al.,
2013) or effects of TBBPA on hormone-sensitive parameters
(Decherf and Demeneix, 2011). These concerns are tempered by
the fact that 70–80% of TBBPA produced is not used as an additive
ﬂame retardant, but as a reactive ﬂame retardant, which is
covalently incorporated into electronic circuit board polymers,
thus reducing its human and environmental bioavailability (ECB,
2006). Only 20–30% of the TBBPA produced is used as an additive
ﬂame retardant in applications and thus subject to environmental
leaching (ECB, 2006). Although in vivo animal toxicity database on
the effects of TBBPA is not indicative that this ﬂame retardant
mediates any substantial inﬂuence on systemic effects, including
endocrine function, at practicable experimental dosages (NTP,
2014; Colnot et al., 2014; Osimitz et al., 2014), the potential effects
of TBBPA on developmental and reproductive functions have not
been examined in a comprehensive fashion.
In order to delineate whether TBBPA in vivo exerts any effects
on reproductive and developmental systems, and to further
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determine whether the endocrine system including thyroid
function and the nervous system are impacted, this investigation
was undertaken to determine the consequences of oral adminis-
tration of TBBPA onthese parameters in CD rats.
2. Materials and methods
2.1. Good laboratory practices
All studies were conducted in accordance with good laboratory
practices (GLP) (United States 40 CFR parts 160 and 179,
Organization for Economic Co-operation and Development C[81]
30 [ﬁnal] Annex 2 and United States Title 21 CFR Part 11 computer
compliance).
2.2. Study method
The studies were conducted in accordance with United States
(US) Environmental Protection Agency (EPA) Ofﬁce of Prevention,
Pesticides and Toxic Substances (OPPTS) test methods 970.3700
(developmental toxicology study) and 970.3800 (reproductive
toxicology study), and Organization for Economic Co-operation
and Development (OECD) guidelines No. 414 (developmental
study) and 416 (reproductive study).
2.3. Test article and vehicle control
The test articles (TBBPA) used in the GLP studies were mixtures
of equal proportions of three different commercial TBBPA products
produced by Albemarle Corporation, Great Lakes Chemical
Corporation and the Dead Sea Bromine Group. Before the initiation
and at completion of dosing, samples of test article were collected
for analysis for identity, composition, purity, homogeneity, and
stability.
In the case of examination for chemical identity,samples were
taken from the middle center of the test article bulk container and
examined by Fourier transform infrared spectroscopy (FTIRS) in
comparison with a standard reference spectrum of TBBPA. The
TBBPA reference spectrumwas derived froma sample of Albemarle
Corporation’s CP 2000 brand of TBBPA, lot number 25948M-1.
Samples for homogeneity and purity testing were collected
from the top, middle and bottom of the test article bulk container.
Purity (% of TBBPA) was determined using high performance liquid
chromatography (HPLC). Test article homogeneity was established
by demonstrating that all 3 samples possessed the same purity
(<5% difference of the TBBPA % purity for each sample compared
with the average TBBPA area % of the three samples).
The samples were further characterized by measuring the
concentration (area %) of tribromophenol, tribromobisphenol-A
and o,p0-tetrabromobisphenol-A. Stability was conﬁrmed by
demonstrating that the composition of the test article before
and after the study did not differ by more than 5%.
The control substance, corn oil, was the vehicle used to prepare
test formulations. Corn oil was purchased fromSpectrumChemical
Manufacturing Corporation (Gardena, California, USA), Spectrum
Laboratories (New Brunswick, New Jersey) and BioServe (French-
town, New Jersey).
2.4. Animal care and maintenance
Male and female CD1 [Crl: CD1 (Sprague-Dawley) IGS BR]
6–8 week-old rats were obtained from Charles River Laboratories
(Portage, MI) and allowed to acclimatize for at least 2 weeks prior
to assignment to the studies. During acclimation, animals were
clinically examined. Animals with any evidence of disease or
physical abnormality were not assigned to the studies.
2.5. Experimental designs
In the multigenerational study, individual parental (P) genera-
tion rats were identiﬁed using an implanted microchip. Offspring
F1 and F2 pups were identiﬁed by paw tattoo on Day 0 of lactation.
Metal ear tag identiﬁcation was used in the developmental
toxicology study. The individual animal number plus the study
number comprised a unique identiﬁcation for each individual
animal. In the reproductive study female rats were 10 weeks and
male rats were 12 weeks of age at the start of mating in the
developmental toxicology study. Rats assigned to the multigener-
ational study were 18 weeks old at the start of mating. Rats were
assigned to the various study groups using a standard, by weight,
block randomization procedure.
In these studies, all rats weremaintained in an environmentally
controlled room. Temperature and relative humidity were main-
tained between 14.4 and 26.1 C and 30–70% respectively. Twelve
hour ﬂuorescent light was provided per day. Water and a rodent
diet (Certiﬁed Lab Diet1meal rodent Chow #5002, PMU Nutrition
International, Inc. St. Louis, Missouri) were freely available to all
animals. The rats were individually housed in suspended, stainless
steel, wire-mesh cages except during parturition and lactation in
the multigenerational study. Females in the multigenerational
study were individually housed in solid plastic cages containing
wood chip bedding from Day 18 of gestation (GSD18) through
GSD21 of the lactation/postnatal period.
Parental males and females were treated with TBBPA prior to
and during mating, and females through gestation, followed by
treatment of pups in accordance with OECD guidelines. The
developmental study was conducted at a separate time, and
included exposure during the period of organogenesis.
2.6. Test formulations and dosing
The test and control formulations were administered in corn
oil by oral gavage once per day, 7 days per week throughout the
studies. Based upon data available from preliminary repeat-dose
sub-chronic and chronic studies, dose levels selected for these
studies were 0, 10, 100 or 1000mg/kg body weight (BW)/day for
the multigenerational study and 0, 100, 300 or 1000mg/kgBW/
day for the developmental investigation. The highest dose
selected did not exceed the maximum tolerated repeated dose
exposure for TBBPA for the current study durations. Fresh batches
of test formulations were prepared weekly and analytically
conﬁrmed by KAR Laboratories Inc. (Kalamazoo, Michigan)
according to GLP.
2.7. In-life examinations
2.7.1. Mortality and cage-side observations performed in all studies
All animals were observed at least twice per day, seven days per
week for evidence of morbidity, mortality, injury, availability of
food, availability of water and any overt evidence of toxicity.
Animals showing signs of severe debility or toxicity were
euthanized. All animals euthanized or found dead underwent full
post mortem evaluation as described below.
2.7.2. Detailed clinical/physical examinations performed in all studies
Mated females in the developmental toxicity studywere given a
detailed clinical/physical examination on a daily basis from
gestation day (GD) 0–20. Parental animals in themultigenerational
study (P and F1 generation) also had a weekly clinical/physical
examination for the duration of the study. The clinical/physical
investigation included, but was not limited to, examination of skin,
fur, eyes, ears, nose, oral cavity, thorax, abdomen, external
genitalia, limbs, feet, respiration and palpation of soft tissues.
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2.7.3. Neurological examination of the F1 parental animals in the
multigenerational study
Ten randomly selected females per dose group were adminis-
tered a detailed neurological examination on GD 9 and 18 and
lactational days (LDs) 4 and 14. All neurological examinationswere
performed blinded to treatment and used standardized procedures
to minimize inter-observer variability and error. The neurological
examinations included but were not limited to: assessment of
markers of parasympathetic function (lacrimation, salivation,
frequency of urination, frequency of defecation), the presence or
absence of piloerection, pupillary light reﬂex, palpebral reﬂex,
evidence of ptosis, the presence or absence of convulsions, the
presence or absence of convulsions, abnormal movement, gait or
posture, muscle tone, unusual/abnormal behaviors, the presence
or absence of stereotypes, abnormal secretions, and forelimb and
hind limb grip strength (Meyer et al., 1979).
2.7.4. Body weight
IndividualbodyweightsweremeasuredonGD0andevery3days
during the gestational phase of the developmental toxicology study.
Individual body weights were measured once pre-test and then at
least weekly during over the course of the multigenerational study.
In the multigenerational study, pregnant females were weighed on
GDs 0, 7, 14 and 20 and LD 0, 4, 7, 14 and 21.
2.7.5. Food consumption
In the developmental toxicology study, food consumption was
measured over GDs 0–3, 3–6, 6–9, 9–12, 12–15, 15–18, 18–20 and
0–20. Food consumption was recorded weekly in the multigener-
ational study except for the period of cohabitation/mating. Food
consumption by mated/pregnant females was measured on GDs 0,
4, 7, 14 and 20 and LDs 0, 4, 7, 14 and 21.
2.7.6. Estrous cyclicity in the multigenerational study
Daily vaginal smears were performed three weeks prior to
mating and until the mating was conﬁrmed or the mating period
ended in P and F1 parental females.
2.7.7. P-generation breeding procedures in the multigenerational
study
P generation animals were individually housed until mating.
After a minimum of 10 weeks of dosing, males and females within
each dosing group were randomly cohabitated with one male per
female for 14 days.Mating occurred in the cage of themale. Vaginal
smears were performed daily during the mating period and the
presence of sperm or a vaginal plug was recorded. The day on
which evidence of mating was ﬁrst observedwas designated as GD
0 and the female was removed from the cage.
2.7.8. P-generation parturition and F1 litter observations in the
multigenerational study
Parental animals were regularly observed for signs of parturi-
tion and allowed to give birth to the F1 generation. The duration of
gestation and any evidence of dystocia wererecorded and the day
on which the F1 pups were delivered was designated lactational
day (LD) 0. Pups were clinically examined in the periparturient
period and the following parameters were recorded: litter size,
number of stillborn pups, number of live born pups, gross
abnormalities, pup body weight and sex. On LD 4, litter size was
reduced by random selection of 8 pups per litter of approximately
equal sex distribution. Cull pups were submitted to post-mortem
study evaluations. The remaining pups were housed with dams
until weaning at LD 21. Dams and pups were observed for survival,
nesting and nursing. Each pup was weighed and examined for
abnormality on LDs 0, 4, 7, and 21. Any intact dead pups were
subjected to post-mortem evaluations.
2.7.9. Selection of the F1 generation and termination of the P
generation in the multigenerational study
At LD21, at least one male and one female from each litter in
each dose group was randomly selected to become F1 parents (a
total of 30 males and 30 females per dose group). All pups were
available for selection and sibling matting amongst the F1 parents
were avoided. All non-selected F1 animals and surviving P
generation females were subjected to post mortem evaluations.
2.7.10. F1 generation pre-mating observations in the
multigenerational study
F1 parentswere individually caged and dosed for 10weeks prior
tomating. Indices of sexual maturation (vaginal opening, preputial
separation) were assessed during this period.
2.7.11. F1 generation mating, gestation and lactation in the
multigenerational study
Following the 10-week pre-mating treatment period the F1
parents were mated and observed as described for the P
generation. Dosing continued through the mating period until
termination. All F1 females continued on treatment until F2 pups
wereweaned and until an assessmentwas performed to determine
if a second mating was required.
2.7.12. F2 generation animal selections in the multigenerational study
Prior toweaning and after standardization of the F2 litter size to
10 pups (5 per sex) on LD4, pups were selected for clinical
examination, motor activity and neuropathology studies. Ten
males and females (at least one male and/or one female per litter)
per dose group were randomly selected and given detailed clinical
examinations on LD 4, 11, and 21 and at 35, 45, 49 and 60 days of
age and at termination of the study. Similarly,10males and females
(at least onemale and/or one female per litter) per dose groupwere
randomly selected and evaluated for motor activity on LDs 13,
17 and 21 and at 602 days of age. Milestones of sexual
development (preputial separation or vaginal opening) were also
evaluated in these animals. Similarly,10males and females (at least
one male and/or one female per litter) per dose group were
randomly selected on LD 11 for neuropathological examination.
After weaning (LD 21) F2 pups were selected on day 22 and day
60 of for auditory startle habituation (10males,10 females per dose
group), and learning and memory (10 males, 10 females per dose
group) evaluation. Milestones of sexual development (preputial
separation or vaginal opening) were also evaluated in all of these
animals. On day 60 of life, F2 pups (10 males, 10 females per dose
group) were selected for detailed neuropathological examination.
Any non-assigned F2 pups were euthanized and subjected to
anatomical pathology examination.
2.7.13. Thyroid hormone analyses in the multigenerational study
At the termination of the P and F1 generations blood was
collected from 10 male and 10 female per dose group (randomly
selected). Serum analyses for thyroid stimulating hormone (TSH),
3,5,30-triiodothyronine (T3) and 3,5,3050-tetraiodothyronine (T4)
were performed. All thyroid hormone analyses were performed by
Laboratory Corporation of America (Burlington, NC USA) according
to GLP. Serum TSH and T4 measurements were performed using
electro-chemiluminescence immunoassay (ECLIA). Serum T3
measurements were performed using cloned enzyme donor
immunoassay (CEDIA).
2.7.14. F2 generation neurobehavioral evaluations in the
multigenerational study
Selected F2 pups underwent detailed neurobehavioral (Func-
tional Observation Battery; FOB) examination according to US EPA
guidelines.
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2.7.15. Postmortem examinations in the multigenerational study
Complete necropsies were performed on: P, F1 and F2 animals
that died spontaneously or were euthanized in extremis, P and F1
generation females that displayed evidence of mating but failed to
deliver, P and F1 generation females that demonstrated no
evidence of mating and failed to deliver, P and F1 that survived
to scheduled termination, F1 and F2 generation pups culled on LD 4,
F1 pups not selected to continue on study, all selected F2 pups at
weaning, all F2 animals used in developmental and behavioral
evaluations, all F2 animals that survived until study termination or
that died.
The following tissues were always collected during necropsies
for subsequent histological examination: adrenal glands, brain,
ovaries or testes, epididymis, grossly discernable lesions, kidneys,
liver, pituitary, prostate glands, seminal vesicles with coagulating
glands, spleen, thymus and uteri (both horns) and cervix, and
vagina. Representative samples of any grossly discernable lesions
and any tissue masses were also collected.
Speciﬁc reproduction parameters examined in the parental (P
and F1 generations) included: number of implantation sites (when
present) for all cohabitated females, stage of estrus, right and left
epididymal weights, right cauda epididymis weight, right testicu-
lar weight and left testicular weight. The left testis and epididymis
were processed for microscopic evaluation using hematoxylin and
periodic acid Schiff staining. The right testis and epididymis were
used for sperm analysis.
The following analyses of the spermatogenic tissues of the
parental (P and F1 generations) were performed: daily sperm
production in the right testis as per the method of (Blazak et al.,
1993), sperm motility in the right vas deferens using the
Hamilton–Thorne Computer Assisted Semen Analysis System
(percent motile and progressively motile sperm), right epididymal
sperm count (sperm concentration per unit mass using hemocy-
tometer counts) and morphology.
Specialized neuropathological examinations were performed
on selected F2 generation animals. Samples of all major brain
regions (olfactory bulbs, cerebral cortices, hippocampus, basal
ganglia, thalamus, hypothalamus, tectum, tegmentum, cerebral
peduncles, brainstem and cerebellum were collected from the
brains from F2 generation animals that were selected for
neuropathology examination on day 11 of life. Brain tissues were
plastic embedded and process for microscopic examination using
hematoxylin and eosin (H&E) staining. Neuropathological exami-
nations included qualitative, semiquantitative as well as simple
morphometric analyses.
Brain morphometric analyses of plastic embedded H&E stained
neurological tissues were performed using digital imaging
captured using a Nikon microscope and SPOT RT Color image-
capturing device (Diagnostic Instruments, Sterling Heights, MI)
and analyzed using SPOT version 3.4.4 for Microsoft Windows
(Diagnostic Instruments, Sterling Heights, MI). The thickness of
various neurological layers (in mm or mm) was determined
linearly by measuring the distance between 2 points on histologic
sections of the brain. Parietal cortex and hippocampal morpho-
metric analyses were performed using one captured image at the
level of the infundibulum from each tissue block at 2
magniﬁcation. The parietal cortex thickness (in mm) was
measured by drawing a line from the meningeal surface to the
layer of neurons that borders the external capsule. The thickness of
the hippocampus (in mm) was measured by drawing a line from
the CA1 region to the ventral line of neurons of the dentate gyrus.
Cerebellar morphometric analyses were performed using one
captured image from one cerebellar lobe from each tissue block at
40magniﬁcation. The external granular layer, themolecular layer
and the combined Purkinje cell and internal granular cell layer
were measured (in mm). Morphometric analyses of the thalamus
were performed using one captured image at the level of the
pontine nuclei at 2magniﬁcation. Thewidth of the thalamus was
measured by drawing a line from the lateral edge of the thalamus
to the center of the mesencephalic aqueducts (i.e. half the overall
width since the entire thalamus did not ﬁt in a single photographic
frame).
Neurological tissues collected from selected F2 generation
animals at 60 days of age included the brain (10 animals per sex per
dose for 10% neutral buffered formalin immersion ﬁxation, and 10
animals per sex per dose for in situ perfusion with 3%
paraformaldehyde and 3% glutaraldehyde in 0.1M phosphate
buffer), both sciatic nerves with tibial, ﬁbular and sural extensions
to the level of the hock, cervical spinal cord and lumbar spinal cord/
proximal sciatic nerves. Neurological tissues were subject to
qualitative microscopic examination (parafﬁn embedded, H&E
stained) and subject to morphometric measurement (plastic
embedded, H&E stained). Particular attention was paid to regions
of the nervous system known to be sensitive to neurotoxic insult or
to those regions likely to be affected, based on the results of the
functional testing. Representative sections of ganglia, dorsal and
ventral root ﬁbers, tibial nerves, sural nerves and ﬁbular nerves
were also evaluated (plastic embedded, H&E stained).
2.7.16. Postmortem evaluations in the developmental toxicity study
All evaluations were performed blinded to treatment. Ovarian
and uterine examinations were performed following post-eutha-
nasia laparohysterectomy. Gravid uterine weight was recorded
and, beginning at the distal end of the left uterine horn, the
location of viable and nonviable fetuses and early and late
resorptions along each uterine horn and the total number of
implantations were recorded. Following opening of the uterine
horns, placentae were examined grossly in situ and fetuses
collected. The numbers of ovarian corpora lutea were counted.
Uteri from females that appeared non-gravid were opened and
placed in 10% ammonium sulﬁde solution for detection of
implantation sites (Kopf et al., 1964).
A necropsy was conducted on each dam. Special emphasis was
placed on structural abnormalities or pathologic changes that may
have inﬂuenced pregnancy. The livers of all maternal animals were
weighed.
Approximately half of the fetuses per litterwere ﬁxed in Bouin’s
solution for subsequent soft tissue examination using the Wilson
razor–blade sectioning technique (Wilson, 1965). The remaining
fetuses in each litter were ﬁxed in ethanol and processed for
staining ofmineralized and cartilaginous tissues using Alizarin Red
S and Alcian Blue and glycerin clearance (Kimmel and Trammell
1981). Fetal ﬁndings were classiﬁed as malformations or develop-
mental variations. In the distribution of fetuses for visceral and
skeletal examinations, every attempt was made to equalize the
ratio of male and female fetuses per litter processed for each
evaluation.
2.8. Statistical analyses
Group pair-wise comparisons were used for the following
endpoints in the multigenerational study: gestation length,
copulatory interval, estrous cycle length, number of estrous cycles,
absolute and relative organ weights (parental and pups; for pups,
the litter was the experimental unit), sperm concentration, daily
sperm production, primordial follicle count, TSH levels, T3 levels,
T4 levels, total uterine implantations (scars), litter size (F1 and F2),
live pups (F1 and F2), age and body weight at preputial separation
(F1), age and body weight at vaginal opening (F1), motor activity,
forelimb and hindlimb grip strength (F2), emotionality (defecation,
grooming, rearing, backing; F2), learning and memory, F2neuro-
pathological observations, and F2 brain morphometry.
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Group pair-wise comparisons were also used for the following
endpoints in the prenatal developmental toxicity study: gestation
body weights, gestation food consumption, absolute and relative
liver weight, gravid uterine weights, corpora lutea counts, total
implantationcounts, viable fetuscounts, andearly resorptioncounts
Group pair-wise comparisons involved examination for homo-
geneity of group variances using Levene’s test (Milliken and
Johnson 1992). If homoscedasticity was established by Levene’s
test (p0.01), Dunnett’s test was used to compare each treatment
group with the control group (Dunnett 1955). If Levene’s test was
signiﬁcant (p<0.01), comparisons with the control group were
made using Welch’s t-test with a Bonferroni correction (Welch
1937). Two tailed tests were used when relevant.
Arcsin-square-root transformation followed by group pair-wise
comparisons was used for the following endpoints in the
multigenerational study: % abnormal sperm, % motile sperm,
pup sex ratios, live birth index stillborn index, and pup survival
indices. This analysis was also used for the following endpoints in
the prenatal developmental toxicity study: fetal sex ratio, % viable
fetuses/implants, % early resorptions/implants, preimplantation
loss, and postimplantation loss. Data comprised % values were
transformed using the arcsin of the square root (Steel and Torrie
1980). Data were then subjected to the group pair-wise compari-
son techniques described above.
Fisher’s exact test was used for the following endpoints in the
multigenerational study: mating indices, fertility indices, fecundi-
ty indices, gestation index, and emotionality (urination; F2). This
statistical method was also used for the following endpoints in the
prenatal development study:malformation by type and total (litter
was the experimental unit), developmental variations by type and
total (litter was the experimental unit), and pregnancy index. For
binomial endpoints (excluding sex ratios), each treatment group
was compared with the control using a Fisher’s exact test with a
Bonferroni correction. Two-tailed tests were used when relevant.
For fetal body weights, litter size was included as a covariate in
the model used to conduct the Dunnett’s test. Each treatment
groupwas comparedwith the control group. Two-tailed tests were
used as appropriate.
Auditory startle habituation data from the multigenerational
study were analyzed using repeated measures (mixed model)
analysis of variance using time as a regression variable (Littell et al.,
1996). If there was no signiﬁcant group-period interaction
(p> 0.05), Dunnett’s test was used to compare the control group
mean averaged over all time periods to each treatment groupmean
averaged over all time points. If the interaction was signiﬁcant
(p<0.05), each time period was analyzed separately using the
group pairwise comparisons methods described above.
Water M-maze endpoints (number of errors and time to
completion) from the multigenerational study were analyzed
using rank transformation followed byanalysis of variance analysis
(ANOVA) (split–split plot design). Historical data onwaterM-maze
data indicated that these endpoints have unpredictable distribu-
tion characteristics, thus analysis would be enhanced by use of a
non-parametric test. Rank transformations were performed for
both of these endpoints (number of errors and time to completion)
for all collection intervals. During ANOVA, data for each sex were
analyzed separately and a split-split plot design was assumed
(Hicks 1982). The model tested for the effects of treatment, days,
trials and all associated interactions. If there were no signiﬁcant
treatment effects (p >0.05) or no signiﬁcant treatment interaction
effects (p > 0.10), no further analysis was conducted. If there was a
signiﬁcant treatment effect or interaction effect involving treat-
ment, the follow-up analyses were performed using the group
pair-wise comparison methods described above.
Table 1
Effect of TBBPA on various reproductive parameters parental generation.
Parameter TBBPA dose mg/kgBW
Control 10 100 1000
Parental generation
Estrus cycle length
(mean SD)
4.80.69 4.60.63 4.60.69 4.40.68
Female mating index 96.7 93.3 93.3 100.0
Female fertility index 80.0 86.7 83.3 96.7
Male mating index 96.7 93.3 93.3 100.0
Male fertility index 80.0 86.7 83.3 96.4
Sperm percent motility
(mean SD)
97.42.01 98.41.25 97.22.29 97.42.21
Sperm percent progressive motility (mean SD) 77.46.21 79.16.70 73.96.10 71.38.68
Total sperm concentration/caudaepididymus108 (mean SD) 3.2620.5391 3.4670.4970 3.1950.5959 3.2560.5856
Percent abnormal sperm
(mean SD)
0.700.934 0.450.562 1.071.187 1.201.595
Table 2
Inﬂuence of TBBPA on various reproductive parameters F1 generation.
Parameter TBBPA dose mg/kg BW
Control 10 100 1000
F1 Generation
Female mating index 100 92.9 86.2 89.3
Female fertility index 86.7 92.9 69.0 75.0
Male mating index 100.0 92.9 86.2 89.3
Male fertility index 86.2 92.9 69.0 75.0
Sperm percent motility
(mean SD)
96.5  3.29 88.120.87* 96.32.85 95.74.92
Sperm percent progressive motility (mean SD) 78.8  5.63 73.518.73 78.96.30 75.99.54
Total sperm concentration/cauda epididymus108 (mean SD) 3.365  0.5380 3.3500.7549 3.3080.6111 2.9410.6338*
Percent abnormal sperm
(mean SD)
0.19  0.489 0.390.550 1.311.064 2.241.935
* Signiﬁcantly different from control p<0.05.
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3. Results
3.1. Parental generation evaluations in the multigenerational study
In the multigenerational study there were no signiﬁcant effects
on mortality, body and tissue weights, clinical observations and
tissue histopathology. As shown in Table 1 (parental) and Table 2
(F1 generation) there were no marked effects on various
reproductive parameters including time to vaginal opening and
anogenital distance. The parental no observed adverse effect level
(NOAEL) was 1000mg/kgBW/day.
Mean serum T3 levels were signiﬁcantly reduced in the high
dose (1000mg/kg BW/day) males (Fig. 1) at the termination of the
P generation. No signiﬁcant effect was noted in the serum T3:T4
[(Fig._1)TD$FIG]
Fig. 1. Serum thyroid hormone parameters (*statistically different from controls, p<0.05) in parental and F1 generation animals at experimental termination. A small
reduction in T3 was present in the high dose parental females. However the greatest effects were reduction of T4 levels in both sexes of the parental and F1 generations at the
100 and 1000mg/kgBW/d exposure levels, and associated increases in the T3:T4 ratio. These changes were not associated with increases in plasma TSH.
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ratio. SerumT4 levelswere reduced in themid (100mg/kgBW/day)
and high dose males and in the high dose females (Fig. 1). This was
associated with a signiﬁcantly increased serum T3:T4 ratio only in
the high dose female group. Serum TSH and T3 levels were not
signiﬁcantly affected by TBBPA treatment. The no observed effect
level (NOEL) for the effects of TBBPA on serum thyroid hormone
levels in the parental generation was 10mg/kgBW/day.It is
noteworthy that thyroid gland histopathology is a more sensitive
indicator of thyroid status compared to T3 or T4 serum concen-
trations (Choksi et al., 2003; Jahnke et al., 2004). There were no
marked histopathological alterations in thyroid or any other
tissues. No estrogenic effects sufﬁcient to affect macro and micro
anatomy, fertility, reproduction, development, survival or behavior
were detected in the embryofetal development study or in the
multigenerational study. No other toxicologically meaningful test
article-related ﬁndings were observed in the P generation.
3.2. F1 generation evaluations in the multigenerational study
Mean serum T4 level was signiﬁcantly reduced in the mid
(100mg/kgBW/day) and high (1000mg/kgBW/day) dose animals
(both males and females; Fig. 1.) at the termination of F1
generation. This was associated with a signiﬁcantly increased
serum T3:T4 ratios in the mid and high dose groups (both male and
female). Serum T3 and TSH levels were not signiﬁcantly affected by
TBBPA treatment. The NOEL for the effects of TBBPA on serum
thyroid hormone levels in the F1 generationwas also 10mg/kgBW/
day. No other toxicologically meaningful test article-related
ﬁndings were observed in the F1 generation.
3.3. F2 generation evaluations in the multigenerational study
Eleven day-old F2 pups derived from F1 dams in the high dose
group (1000mg/kgBW/day) had signiﬁcant thinning of the brain
parietal cortex (at the level of the infundibulum) at day 11 of life
(Fig. 2). Due to the limitations of the image analysis examinations,
these results need to be interpreted with caution. This change was
not associated with histological changes in the parietal cortex and
was not associated with signiﬁcant test-article related changes in
pre-weaning motor activity, step-through passive avoidance test
performance, auditory startle test performance, forelimb and hind
grip strength, emotionality, grooming behaviors, rearing, backing or
[(Fig._2)TD$FIG]
Fig. 2. Brain parietal thickness (*statistically different from controls, p<0.05) in F2 generation 11-day old pups. Oral exposure to 1000mg/kgBW/day TBBPAwas associated
with signiﬁcant reduction of thickness of the brain parietal cortex at the level of the infundibulum. This change was not associated with histologic changes in the parietal
cortex and was not associated with signiﬁcant test-article related changes in pre-weaning motor activity, step-through passive avoidance test performance, auditory startle
test performance, forelimb and hind grip strength, emotionality, grooming behaviors, rearing, backing or water M-maze performance. Due to the limitations of the image
analysis examinations, these results need to be interpreted with caution.
Table 3
Benchmark dose (BMD) continuous modeling of the female rat parietal cortex thinninga.
Continuous
Modelb
Speciﬁed
effect
BMD BMDL p-value test 1:
lack dose
response?
p-value test 2:
constant
variance?
p-value test 3:
good variance
model?
p-value for ﬁt: does the
model for the mean ﬁt?
Visual ﬁt Scaled
residual of
interest
AIC
Exponential 2 0.1 7.0E + 02 5.1E + 02 0.002 0.279 0.253 0.108 Moderate 0.04 105
Exponential 3 0.1 7.0E + 02 5.1E + 02 0.002 0.279 0.253 0.108 Moderate 0.04 105
Exponential 4 0.1 7.0E + 02 1.6E + 02 0.002 0.279 0.253 0.108 Moderate 0.04 105
Exponential 5 0.1 7.0E + 02 1.0E + 02 0.002 0.279 0.253 0.035 Moderate 0.04 103
Hill 0.1 7.2E + 02 5.3E + 02 0.002 0.279 0.253 0.035 Moderate 0.04 103
Linear 0.1 7.2E + 02 5.3E + 02 0.002 0.279 0.253 0.109 Moderate 0.04 105
Polynomial 0.1 8.2E + 02 5.3E + 02 0.002 0.279 0.253 0.035 Moderate 0.02 103
Polynomial 0.1 7.8E + 02 5.3E + 02 0.002 0.279 0.253 0.035 Moderate 0.02 103
Power 0.1 7.2E + 02 5.3E + 02 0.002 0.279 0.253 0.109 Moderate 0.04 105
a One standard deviation of the mean is assumed for the Benchmark response (BMR).
b Complete information on this modeling effort is available upon request.
R.B. Cope et al. / Toxicology 329 (2015) 49–59 55
water M-maze performance. The effect on brain parietal cortex
thickness was also not observed at later stages of development. The
NOEL for brain parietal cortex thinning at day 11 of life in the F2
generation was 100mg/kgBW/day. Benchmark doses (BMDs) were
developedfromthesedatausingsoftware freelyavailable fromtheU.
S. Environmental Protection Agency (http://www.epa.gov/ncea/
bmds/dwnldu.html). BMDs of approximately 700mg/kg-day (lower
95% limit of 160mg/kg-day) for females, and 170mg/kg-day (lower
95% limit of 73mg/kg-day) formaleswere determined (Tables 3 and
4, respectively). No other toxicologically meaningful test article-
related ﬁndings were observed in the F2 generation. Speciﬁc details
of these ﬁndings can be found in the Supplemental materials.
3.4. Fetal evaluations in the prenatal development study
This study was done according to GLP and monitored a
sufﬁcient number of parameters to afford conﬁdence to these
results. Data in Table 5 clearly demonstrate that none of the
maternal and fetal parameters were markedly affected. Thus, the
NOEL for prenatal effects was 1000mg/kg BW/day.
4. Discussion
Both prenatal development and multigenerational toxicology
studies demonstrated that TBBPA is not an adult maternal toxicant
nor an overt teratogen at oral doses of up to 1000mg/kgBW/day in
CD1 [Crl: CD1 (Sprague-Dawley) IGS BR] rats. In brief, TBBPA is
thus not considered a developmental toxicant in rats. Similarly, the
multigenerational study was conducted according to GLP and also
produced negative results for numerous parameters. However, this
study did show thinning of the brain parietal cortex in F2
generation animals at day 11 of life at the maternal oral dose of
1000mg/kgBW/day. The NOEL for this effect was thus the
maternal oral dose of 100mg/kgBW/day. The multigenerational
Table 4
Benchmark dose (BMD) continuous modeling of the male rat parietal cortex thinning.a
Continuous
modelb
Speciﬁed
effect
BMD BMDL p-value test 1:
lack dose
response?
p-value test 2:
constant
variance?
p-value test 3:
good variance
model?
p-value for ﬁt: does the
model for the mean ﬁt?
Visual ﬁt Scaled
residual of
interest
AIC
Exponential 2 0.1 4.3E + 02 3.4E + 02 <0.0001 0.15 0.15 0.33 Moderate 1.04 118
Exponential 3 0.1 4.3E + 02 3.4E + 02 <0.0001 0.15 0.15 0.33 Moderate 1.04 118
Exponential 4 0.1 1.7E + 02 8.0E + 01 <0.0001 0.15 0.15 0.50 Good 0.07 117
Exponential 5 0.1 1.7E + 02 8.0E + 01 <0.0001 0.15 0.15 0.50 Good 0.07 117
Hill 0.1 1.7E + 02 7.3E + 01 <0.0001 0.15 0.15 0.51 Good 0.08 117
Linear 0.1 4.6E + 02 3.8E + 02 <0.0001 0.15 0.15 0.29 Moderate 1.10 117
Polynomial 0.1 4.6E + 02 3.8E + 02 <0.0001 0.15 0.15 0.29 Moderate 1.10 117
Polynomial 0.1 4.6E + 02 3.8E + 02 <0.0001 0.15 0.15 0.29 Moderate 1.10 117
Power 0.1 4.6E + 02 3.8E + 02 <0.0001 0.15 0.15 0.29 Moderate 1.10 117
a One standard deviation of the mean is assumed for the Benchmark response (BMR).
b Complete information on this modeling effort is available upon request.
Table 5
Inﬂuence of TBBPA on reproductive and pre-natal developmental parameters.
Endpoint evaluated TBBPA dose
Control 100mg/kgBW/day 300mg/kgBW/day 1000mg/kgBW/day
Number of females on study 25 25 25 25
Number not pregnant 0 1 0 1
Number pregnant 25 24 25 24
Pregnancy index 100.0 96.0 100.0 96.0
Number died during pregnancy 0 0 1 0
Number of abortions 0 0 0 0
Number of early deliveries 0 0 0 0
Number of females with viable fetuses on day 20 gestation 25 24 24 23
Number of coprora lutea per animal (mean SD) 16.8  2.72 16.6  2.21 16.8  3.60 18.0  2.57
Number of implantation sites per animal (mean SD) 15.4  1.76 15.3  2.48 15.4  3.52 15.6  8.059
Preimplantation loss %/animal (mean SD) 7.25  7.540 7.77  9.699 10.18  15.696 10.65  8.059
Viable fetuses number/animal (mean SD) 14.6  1.68 14.5  2.64 14.1  3.71 14.3  3.43
Viable fetuses/implant %/implant (mean SD) 95.05  6.636 94.63  7.523 92.34  12.560 90.25  20.023
Fetal sex ratio; % males/animal (mean SD) 52.9  12.20 50.7  15.95 47.5  16.58 52.5  13.64
Postimplantation loss; %implants/animal (mean SD) 4.95  6.636 5.37  7.523 7.66  12.560 9.75  20.023
Non-viable fetuses; number/animal (mean SD) 0.0  0.00 0.0  0.00 0.0  0.00 0.0  0.00
Early resporptions; number/animal (mean SD) 0.8  1.12 0.8  1.13 1.3  2.01 1.3  1.73
Early resoprtions/implant; %/impant (mean SD) 4.95  6.636 5.37  7.523 7.68  12.560 9.75  20.023
Late resorptions; number/animal 0.0  0.00 0.0  0.00 0.0  0.00 0.0  0.00
Gravid uterine weight (g; mean SD) 83.0  8.21 81.3  14.17 77.5  19.54 83.7  9.71
Male fetal weight (mean SD) 3.81  0.258 3.81  0.319 3.67  0.240 3.75  0.357
Female fetal weight (mean SD) 3.62  0.262 3.63  0.276 3.53  0.208 3.56  0.293
Male + female fetal weight (mean  SD) 3.72  0.254 3.72  0.296 3.59  0.221 3.66  0.322
Forelimb external observations
Digits, ectrodactyly malformations
Number of litters (%)
0 0 0 0
Digits, ectrodactyly malformations
Number of foetuses (%)
0 0 0 0
Abnormal forelimb ﬂexure variations
Number of litters (%)
0 0 1 0
Abnormal forelimb ﬂexure variations
Number of foetuses (%)
0 0 1 0
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study also demonstrated changes in thyroid T4 hormones levels in
both the parental and F1 generations. The NOEL for these changes
is 10mg/kgBW/day. These ﬁndings are consistent with the
observations of an extensive review of currently available TBBPA
neurological data by Williams and DeSesso (2010) that demon-
strated no adverse effects attributable to TBBPA exposures up to
and including 1000mg/kgBW/day on neurodevelopment, neuro-
motor functions, learning, memory, and neurobehavioral end-
points.
It is noteworthy that thinning of the brain parietal cortex in the
F2 generation at post-natal day (PND) 11 was not associated with
lesions or changes that were detectable by H&E histological
examination. Further, morphometric alterations in the brain
parietal cortex were not associated with any signiﬁcant effects
on forelimb and hind limb grip strength between PND4–60, motor
activity PND13–60, step through passive avoidance behavior at
PND 22 and 60, water M-maze performance at PND day 110 or
auditory startle habituation at PND 22 and 60. Thus the NOEL for all
neuro-functional examinations is 1000mg/kgBW/day.
However, transient (reversible) effects on brain neuronal
development in the hippocampal dentate gyrus have been
observed in Sprague-Dawley rats exposed to 1000mg/kgBW/day
of TBBPA (Saegusa et al., 2012). Thus, it could be that the thinning
of the brain parietal cortex in the F2 generation observed in this
study at postnatal day 11might be a transient effect that resulted in
no subsequent detectable functional and pathological deﬁcits. It is
also conceivable that this ﬁnding was simply due to chance. In any
case the biological relevance is not clear as there were no
consequent associated neurological and functional alterations. In
the absence of detectable lesions or change and no apparent effects
on function, the ﬁnding of brain parietal cortex thinning on day
11 of life in the F2 generation needs to be interpreted with caution,
particularly because of the limitations of the morphometric
technique used. Morphometric measurements were only taken
from one section of the parietal cortex per animal, at only one time
point during development and by using single line transect
sampling.
At the termination of the P and F1 generations, decreased serum
total T4 levels and elevated T3:T4 ratios were evident at doses of
100mg/kgBW/day. Notably, blood TSH levels were not markedly
altered despite the presence T3:T4 ratios >27. It should be noted
that TBBPA exposure did not signiﬁcantly affect serumT3 levels and
that elevations in the T3:T4 ratioswere due simply to a lower serum
T4 concentration. Similar ﬁndings were reported from a one
generation reproduction study in Wistar rats (Van der Ven et al.,
2008) and studies in male Sprague-Dawley rats (Choi et al., 2011).
A comprehensive National Toxicology Program investigation on
the effects of TBBPA was recently conducted. In a 3-month daily
oral gavage study at doses of 0, 10, 50, 500, or 1000mg/kg
administered to F344/NTAC rats for 14weeks, a decreasewas noted
in T4 levels at day 4 and week 14 at only 500 and 1000mg/kg/d in
both genders. In agreement with our ﬁndings there were no
treatment-related histopathological lesions and no marked
changes reported in TSH and T3 levels. Further, in an oral gavage
study in B6C3F1/N mice daily administration of 0, 10, 50, 100, 500,
or 1000mg/kg/day TBBPA did not markedly affect T4, T3 and TSH
levels or histopathology. Recently Osimitz et al. (2014) in a 90 day
oral gavage administration of 0, 100, 300 or 1000mg/kg/d TBBPA
also found this ﬂame retardant at 100mg/kg and higher there was
reduced T4 but no effect on the levels of T3 and TSH and thyroid
tissue histopathology in CD rats. It is of interest that in rats given
1000mg/kg/d for 90 days and then allowed to recover with no
TBBPA for 6 weeks the levels of T4 were similar to control
indicating that the observed change in T4 was transient and not
related to any functional alterations. In a 2-year carcinogenesis
study usingWistar Han rats or B6C3F1/Nmice administration of 0,
250, 500 or 1000mg/kg/day TBBPA there was no evidence of
increased pathological alterations in thyroid tissue such as cyst,
C-cell hyperplasia, follicle hyperplasia, inﬂammation, and follicular
adenoma in thyroidal tissue in both species and genders. Data on
thyroid hormone levels were not reported.The NTP study
reafﬁrmed that the thyroid gland is not a target tissue following
sub-chronic and chronic exposure in mice and rats. In agreement
with the NTP 2-year study, the relevance of the T4 changes
observed in our investigation remain unclear but it is evident there
were no associated physiological functional alterations.
Serum T4 represents a circulating thyroid hormone reserve
since it is a pro-hormone, with T3 being the ultimate hormone
(Larsen and Zavacki 2012; Marsili et al., 2011). Thus, the changes
observed in the current multigenerational study, primarily T4,
represent a reduction in the circulating thyroid hormone
functional reserve pool rather than a decrease in circulating pool
of the ultimate T3 hormone (Larsen and Zavacki 2012;Marsili et al.,
2011). This interpretation is consistent with the lack of any
evidence of overt thyroid disease such asovert hypothyroidism as
evidenced by lack of histopathology and changes in circulating TSH
and T3. Overt hypothyroidism did not occur in the multigenera-
tional study because the circulating ultimate hormone T3 pool was
not depleted to a biologically signiﬁcant level (i.e., T3 was only
statistically signiﬁcantly lower in males of the parent generation).
Further, measurements of serum thyroid hormone levels are
essentially screening-level assessments of thyroid function.
Thyroid histopathology and scintigraphic techniques provide
greater sensitivity and substantially more comprehensive infor-
mation regarding thyroid function and dysfunction (Choksi et al.,
2003). It should be clearly noted that no anatomical thyroid
abnormality was detected in any of the animals in the multigener-
ational study. This ﬁnding was reafﬁrmed in several sub-chronic
and chronic NTP (2014) studies in mice and rats.
In addition, there are numerous investigations that demon-
strate that in humans functionally signiﬁcant changes in T4
production during development are accompanied by developmen-
tal delay, low body mass, brain developmental abnormalities and
neurobehavioral developmental disorders (Di Liegro 2008; For-
head and Fowden 2014; Koibuchi 2013; Negro et al., 2011).
However, there was clearly no evidence of prenatal or postnatal
developmental delay, reduced body mass or reduced weight gain
in either the prenatal development or multigenerational studyin
rats administered TBBPA. Apart from limited evidence of thinning
of the parietal cortex at postnatal day 11 using a crude screening-
level morphometric method that resulted in no apparent
neurological, neurodevelopmental or neuroperformance effects,
there is clearly no evidence of brain developmental abnormality or
neurobehavioral developmental disorders in this multigeneration-
al study. Thus, while circulating T4 functional thyroid reserve pool
may have been reduced in the P and F1 generations in the
multigenerational study, the effects were clearly not adverse as
measured by other parameters in this study.
The combination of lowered serum T4, increased serum T3:T4
ratios, normal serum T3 and normal serum TSH levels (i.e. no
compensatory increase in TSH in response to lowered T4) was
previously observed in several rat strains following xenobiotic
stimulated induction of hepatic microsomal enzymes (Richardson
and Klaassen, 2010). T4 is selectively inactivated by glucuronida-
tion via hepatic microsomal UDP glucuronyltransferase (UGT) 1A
and other 3-methylcholanthrene inducible UGTs in several rat
strains (Beetstra et al., 1991; Richardson and Klaassen, 2010; Visser
et al., 1991, 1993). T3 is selectively inactivated by pregnane X
receptor (PXR) inducible hepatic microsomal UGT2B2 rather than
UGT1A in several rat strains (Beetstra et al., 1991; Hood and
Klaassen, 2000; Richardson and Klaassen, 2010; van Raaij et al.,
1993; Visser et al., 1993). Selective induction of UGT1A and other
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3-methylcholanthrene inducible UGTs in the absence of induction
of UGT2B2 results in a fall in serum T4 levels without concurrent
decreases in serum T3 and without concurrent compensatory
increases in serum TSH in rats (Hood et al., 1999; Hood and
Klaassen, 2000; Richardson and Klaassen, 2010). However,
selective induction of UGT2B2 by PXR agonists is followed by a
fall in serum T3 levels and a marked compensatory increase in TSH
(Hood et al., 1999; Hood and Klaassen, 2000; Richardson and
Klaassen, 2010). Thus, it is apparent that, at least in some rat
strains, selective hepatic microsomal UGT1A induction by xeno-
biotics (notably3-methylcholanthrene) results in reduction of
serum T4 without concurrent decreases in serum T3 and without
concurrent compensatory increases in serum TSH (Richardson and
Klaassen, 2010). It should be noted that these effects have only
been observed in rodents and are yet to be demonstrated in
humans.
In this study, decreases in serum T4 in the general absence of
concurrent changes in serum T3 and in complete absence of
concurrent compensatory increases in serum TSH observed in the
multigenerational study appear to be due to TBBPA selective
induction of rat hepatic microsomal UGT1A and other
3-methylcholanthrene inducible UGTs (i.e., hypothesis #2). The
implications of this hypothesis and the ﬁndings of the multigen-
erational study are that CD1 [Crl: CD1 (Sprague-Dawley) IGS BR]
rats should be resistant to TBBPA-induced thyroid follicular
changes, including carcinogenesis, since such changes and tumors
are largely driven by excessive and sustained TSH stimulation in
this species (IARC, 1997; Parkinson et al., 2013). Further, the NTP
(2014) study described above showed that TBBPA did not produce
thyroid follicular hyperplasia in a 2-year carcinogenesis studies in
rat and mouse. These observations are consistent with the known
threshold effects of other possible thyroid toxicants.
A recent human health risk assessment for TBBPA demonstrat-
ed a worst-case scenario, highest adult European human exposure
level of 0.19mg/kgBW/day (ECB, 2006). Accordingly, this implies a
worst-case margin of exposure (MOE) of 10/0.19ﬃ50 or 100/
0.19ﬃ500 depending onwhether the dose of 10 or 100mg/kgBW-
day is considered to be a no observed adverse effect level (NOAEL)
based upon changes in thyroid hormone levels in the absence of
other indications of thyroid insufﬁciency. A worst-case scenario,
based on deﬁning the thinning of the parietal cortex at postnatal
day 11 at 1000mg/kgBW-day in the 2-generation study as a lowest
observed adverse effect level (LOAEL), would be 5000 (i.e.,
MOE=100/0.19ﬃ500). A recent risk assessment by Colnot et al.
(2014) demonstrated adult human exposure levels to be only a few
ng/kg BW/day. Based on the Colnot et al. (2014) assessment, the
MOE is in the 106 to 105 range and the LOAEL:exposure ratio is in
the 107 range. In general, since a MOE of 100 is desirable, these
results indicate a more than acceptable MOE for adult humans,
even in the presence of an absolute, worst-case exposure scenario.
Benchmark doses (BMDs) that were developed for thinning of the
parietal cortex could also be used in this evaluation of MOE
(Tables 3 and 4).
Based on the same European risk assessment, the average daily
uptake by a breast feeding human infant (ADUInfant) for the
0–3 month and 3–12 month periods of development were
0.044103 and 0.017103mg/kg BW/day respectively (ECB,
2006). Thus the NOEL (maternal exposure):ADUInfant ratios (also
referred to as a MOEs by some regulatory agencies) are >2106. A
recent Canadian human health risk assessment reported higher
human infant exposure levels than those reported in Europe with
the highest upper bound estimate of ADUInfant being 1.95104
mg/kg BW per day (Health-Canada, 2013). This would still result in
a NOEL (maternal exposure):ADUInfant ratio of >5105. These
estimates are consistent with other published risk assessments
(Colnot et al., 2014).
It should be noted that these simple screening-level approaches
do not take into account the lower sensitivity of humans compared
with rats to the thyroid effects, due to the rat lower “thyroid
efﬁciency” (Parkinson et al., 2013). Speciﬁcally, the plasma T1/2 of T3
and T4 in the rat is considerably shorter than in humans due to
protection of circulating thyroid hormones by the protein
chaperone thyroxine binding globulin (TBG) in humans (Parkinson
et al., 2013). TBG is not present in rats. Accordingly, rats
compensate for the more rapid turnover circulating thyroid
hormones by secreting more TSH resulting in more T4 production
(Parkinson et al., 2013). In effect, rats need to have a 10-fold higher
rate of T4 production on a per unit bodymass basis than humans in
order to maintain physiological homeostasis (Parkinson et al.,
2013). Accordingly it is probable that humans are resistant to the
effects of TBBPA on T4 compared with CD1 [Crl: CD1 (Spragu-
Dawley) IGS BR] rats, implying that the actual MOE for adult
humans may be substantially larger than 50–500.
Consistent with the results of other published rodent studies
(Kang et al., 2009; Saegusa et al., 2009; Tada et al., 2006; Van der
Ven et al., 2008), TBBPA was not nephrotoxic at oral exposures of
up to 1000mg/kgBW/day in the current rat prenatal development
and multigenerational studies. Notably, this is not consistent with
the ﬁndings of Fukuda et al. (2004) that demonstrated persistent
TBBPA-induced nephrotoxicity in rats dosed at 200 or 600mg/
kgBW/day between days 4 and 21 of life.
5. Conclusions
This developmental toxicology study demonstrated that TBBPA
exerted nomarked developmental effects at oral gavage doses of up
to and including 1000mg/kgBW/day, the highest dose tested. The
multigenerational study also was without any signiﬁcant repro-
ductive effects and was without all but one histopathological
alteration at doses of 1000mg/kgBW/day. The sole histopathol-
ogy lesionwas thinning of the brain parietal cortex in F2 generation
animals at PND 11 at thematernal oral dose of 1000mg/kgBW/day.
This effect was not accompanied by any detectable neurodevelop-
ment, neurofunctional or neurobehavioral deﬁcits and needs to be
interpreted with caution given the limitations of brain morpho-
metric techniques used. The multigenerational study also showed
decreases in serumT4 in the general absence of concurrent changes
in serum T3 and in the complete absence of concurrent
compensatory increases in serum TSH as well as lack of
histopathological alterations. This pattern of change in serum
thyroid hormones has been observed with other xenobiotics in
rodents and is suggestive of selective induction of hepatic
microsomal UGT1A in the absence of induction of UGT2B2, a
pathway not yet observed in humans.
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